Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00782002 · ClinicalTrials.gov registry record · Phase 1

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

A Phase 1 study of Advanced Solid Tumors, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
2
Study locations

NCT00782002 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Eli Lilly and Company. The registered enrollment target is 27 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00782002, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.

Conditions Studied

Advanced Solid Tumors

Interventions

  • BIOLOGICAL IMC-18F1

Study Locations (2)

Michigan

  • ImClone Investigational Site - Detroit

Ohio

  • ImClone Investigational Site - Cleveland

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2006-07
Est. Completion 2009-11
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00782002

The ClinicalTrials.gov registry entry for NCT00782002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (86% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IMC-18F1 is the first listed.

NCT00782002 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Ohio.

Frequently Asked Questions

What is clinical trial NCT00782002 about?

NCT00782002 is a clinical study titled "Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy". The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.

What is the current status of trial NCT00782002?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-07. Estimated completion is 2009-11.

What conditions does trial NCT00782002 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00782002?

The interventions under investigation include: IMC-18F1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00782002?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00782002 being conducted?

This trial has 2 study locations across Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.